Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
16 November 2016
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system ...
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
11 November 2016
Company: REPROCELL, Inc. (JASDAQ Company code: 4978) Representative: CEO Chikafumi Yokoyama Inquiries: CFO Daisuke Usui (TEL.045-475-3887) Today, REPROCELL Inc. (“REPROCELL”) has entered into a partnership with Steminent Biotherapeutics Inc...
REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex
16 September 2016
REPROCELL Europe has won the Corporate Vision Technology Innovation Award 2016 for Alvetex technology for 3D cell culture. The following is CV Magazine’s interview with REPROCELL Europe’s CSO Professor Stefan Przyborski. MOST RENOWNED FOR I...
Prof Stefan Przyborski speaking at BBS 2016 Biennial Meeting
06 July 2016
ReproCELL Europe Ltd’s Chief Scientific Officer Prof Stefan Przyborski is giving a public lecture on “Scaffold Cell Culture Technology for Generation of In Vivo-like Tissue Models” at the British Biophysical Society 2016 Biennial Meeting 6t...
REPROCELL Europe’s (formerly Reinnervate’s) CSO Prof Stefan Przyborski to give an Alvetex Seminar at the University of Oxford, 24 May 2016
20 May 2016
Professor Stefan Przyborski, Chief Scientific Officer of REPROCELL Europe (formerly Reinnervate), is to give a seminar on Alvetex next week, 24th May 2016. Venue: Large Lecture Theatre Le Gros Clark Building Department of Physiology, Anatom...
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
13 May 2016
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD)...
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
21 April 2016
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease. Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopt...
Reinnervate Ltd wins Corporate Vision’s 2015 Technology Innovator Award for Alvetex
22 March 2016
We are pleased to announce that Reinnervate Ltd has been awarded Corporate Vision’s 2015 Technology Innovator Award for Alvetex 3D cell culture. Alvetex has been awarded the title, “Most Advanced 3D Cell Technology.” The awards have been an...
Alvetex in Space
14 January 2016
While the first British ESA astronaut Tim Peake is currently on the International Space Station (ISS) and is about to make his first spacewalk, now is a good time to mention again that Reinnervate’s flagship product, Alvetex® Scaffold, has ...
REPROCELL acquires Biopta to expand its drug discovery services
25 November 2015
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta. The acquisition of Biopta and its US subsidiary, Biopta Inc. is expected to complete on the 10th of Decem...